Physician profile
Eric R Kavosh
NPI 1164683249
$11,718.90
in general payments reported to CMS, 2019-2025
26 companies · $1,333 in 2025
The $1,333 reported for 2025 was more than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $740 · 2020: $620 · 2021: $1,062 · 2022: $1,358 · 2023: $3,095 · 2024: $3,512 · 2025: $1,333.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,981 · Travel and Lodging: $2,854 · Education: $104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,981.13 |
| Travel and Lodging | $2,853.87 |
| Education | $104.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $5,688.80 | 2021-2025 | Xeomin |
| Regeneron Healthcare Solutions, INC. | $1,305.50 | 2019-2025 | Dupixent |
| Genzyme Corporation | $706.59 | 2019-2025 | |
| Pfizer INC. | $629.83 | 2019-2024 | |
| Galderma Laboratories, L.P. | $576.21 | 2019-2025 | Dysport, Nemluvio |
| Glaxosmithkline, LLC. | $495.51 | 2019-2025 | Nucala, Shingrix, Arexvy |
| Optinose US, INC. | $388.52 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $324.19 | 2019-2025 | Tezspire, Airsupra |
| Amgen INC. | $209.55 | 2021-2025 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $200.25 | 2020-2024 | Cuvitru |
| Novartis Pharmaceuticals Corporation | $179.84 | 2021-2025 | |
| Abbvie INC. | $170.53 | 2021-2025 | |
| Pharming Healthcare, INC. | $169.40 | 2022-2023 | Ruconest |
| Allergan, INC. | $107.31 | 2019-2022 | |
| Alk-Abello, INC | $84.58 | 2019-2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Revance Therapeutics, INC. | $57.03 | 2024-2025 | Daxxify, Daxi |
| Teva Pharmaceuticals USA, INC. | $55.33 | 2021-2022 | |
| Shire North American Group INC | $53.73 | 2019 | |
| Csl Behring | $51.59 | 2022-2024 | Hizentra, Privigen |
| Musculoskeletal Transplant Foundation INC. | $47.22 | 2019 | |
| Ars Pharmaceuticals Operations, INC. | $46.54 | 2025 | Neffy |
| Intersect Ent, INC. | $46.39 | 2019 | |
| Octapharma USA, INC. | $43.19 | 2020-2022 | |
| Grifols USA, LLC | $42.52 | 2024 | Gamunex-C, Xembify |
| Kaleo, INC. | $24.63 | 2020-2023 | Auvi-Q |
| Merck Sharp & Dohme LLC | $14.12 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Kavosh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.